## 4 Results and Conclusions
\begin{table}
\begin{tabular}{c c c c c c c c} \hline  & **Case 1** & **Case 2** & **Case 3** & **Case 4** & **Case 5** & **Case 6** & **Case 7** \\ \hline Age (years) & 15 & 12 & 12 & 17 & 16 & 13 & 11 \\ \hline Sex & F & F & F & F & M & M & M \\ \hline Coexisting allergic & Allergic asthma, food & & & & & & \\ diseases & allergy & & & & & & \\ \hline Pretreatment total & & & & & & & \\ serum IgE, KU/L & & & & & & & \\ \hline Post-treatment & & & & & & & \\ total serum IgE, & & & & & & & \\ total serum IgE, & & & & & & & \\ KU/L & & & & & & & \\ \hline Pretreatment blood & & & & & & & \\ eosinophil count, & & & & & & & \\ cells/mm\({}^{3}\) & & & & & & & \\ \hline Post-treatment blood & & & & & & & \\ eosinophil count, & & & & & & & \\ coils/mm\({}^{3}\) & & & & & & & \\ \hline Pretreatment AD & & & & & & & \\ clinical scores & & & & & & & \\ EAIS & 33 & 12.2 & 30.1 & 11.6 & 6 & 38.4 & 29.8 \\ SOORAD & 50 & 52.5 & 68.4 & 16 & 12 & 70.4 & 53 \\ P-INS & 6 & 6 & 10 & 8 & 4 & 9 & 10 \\ S-INS & 7 & 0 & 0 & 0 & 0 & 10 & 10 \\ cDLQI & 19 & 19 & 10 & 12 & 0 & 22 & 6 \\ \hline Post-treatment AD & & & & & & & \\ clinical scores & & & & & & & \\ EASI & 18 & 0 & 9.3 & 0 & 4 & 19.8 & 7.4 \\ SCOORAD & 33 & 22.8 & 28.4 & 6 & 8 & 19 & 36 \\ P-INS & 3 & 3 & 1 & 2 & 2 & 5 & 7 \\ S-INS & 4 & 0 & 0 & 0 & 0 & 7 & 0 \\ cDLQI & 6 & 5 & 5 & 4 & 0 & 4 & 3 \\ \hline \end{tabular}
\end{table} 
Table 1: General characteristics of the study population. \begin{table}
\begin{tabular}{c c c c c c c c} \hline  & **Case 1** & **Case 2** & **Case 3** & **Case 4** & **Case 5** & **Case 6** & **Case 7** \\ \hline AD treatment before & Motivarizers, TCs, & Motivarizers, & Motivarizers, TCs & Motivarizers, TCs, & Motivarizers, TCs & Motivarizers, TCs & Motivarizers, TCs \\ duplumb & TCs, SCs, CsA & TCs & Motivarizers, TCs & TCs & TCs, SCs & Motivarizers, TCs & Motivarizers, TCs \\ \hline AD treatment & & & & & & & \\ after 3 months & Motivarizers, TCs & Motivarizers, TCs & Motivarizers & Motivarizers & Motivarizers, TCs & Motivarizers, TCs \\ \hline Asthma evaluation & & & & & & & \\ before duplumb & & & & & & & \\ PVC (L) & 2.44 & / & / & 3.00 & 6.07 & / & / \\ FVC 2 score & 1.40 & / & / & \(-1.45\) & 1.80 & / & / \\ FEV1 (L) & 2.12 & / & / & 2.70 & 4.60 & / & / \\ FEV 2 (L) & 1.29 & / & / & \(-1.97\) & 0.61 & / & / \\ ACT & 19 & / & / & 20 & 21 & / & / \\ \hline Asthma evaluation & & & & & & & \\ after 3 months & & & & & & & \\ FVC (L) & 2.76 & / & / & 3.70 & 4.92 & / & / \\ FVC 2 score & 0.95 & / & / & \(-0.07\) & \(-0.75\) & / & / \\ FEV1 (L) & 2.50 & / & / & 295 & 3.60 & / & / \\ FEV1 2 score & 1.24 & / & / & \(-0.95\) & \(-1.78\) & / & / \\ ACT & 23 & / & / & 25 & 25 & / & / \\ \hline Treatment for asthma & ICS, & / & / & ICS-LABA, & & & \\ before duplumb & antihistamines & & & & & & \\ \hline Treatment for asthma & & & & & & & \\ after 3 months & ICS & / & / & ICS, antihistamines & & & \\ \hline Side effects of & Headache, & & & & & & \\ duplumb & conductivities & None & None & Injection site reaction & None & Conjunctivtivits & None \\ \hline \end{tabular}
\end{table} 
Table 1: _Cont._In addition, recent evidence has suggested new potentially preventive functions of dupilumab [22]. An early administration of dupilumab from the first months of life may play a pivotal role in slowing or interrupting the progression of the atopic march towards asthma [20]. In this regard, a meta-analysis of 12 clinical trials including 3525 patients (mean age, 35 years; range, 12-88 years) sought to define the risk of developing new or worsening allergic events for dupilumab compared to placebo in patients with AD. The authors observed a marked reduction in both the incidence of new allergies and the worsening of pre-existing allergic conditions in patients, especially children with an early-onset AD (2 years), treated with dupilumab compared to controls [22]. In our case series, patients with AD and asthma receiving dupilumab (cases 1, 4 and 5) started treatment at 15, 17 and 16 years, respectively.